Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety

Bibliography

• TURNER-WARWICK M, HODSON ME, CORRIN B, KER IH:Clinical Atlas of Respiratory Disease. Gower Medical Pub-lishing, London, UK (1990).
   Google Scholar
• SKUDLARSKA BA, SCOTT GC: The role of antibiotics inthe management of acute exacerbations of chronic bronchitis: answers to some commonly asked ques-tions. Mole. Med. (1992) 89:289–293.
   Google Scholar
• BALL P, HARRIS JM, LOWSON D, TILLOTSON G, WILSONR: Acute infective exacerbations of chronic bronchitis. Quart. J. Med. (1995) 88:61–68.
   Google Scholar
• NICOTRA MB, KRONENBERG RS: Con: antibiotic use in exacerbations of chronic bronchitis. Sem. Resp. Med. (1993) 8:254–258.
   PubMedGoogle Scholar
• COLE P: Evaluating the clinical outcomes of respira-tory infection. Intl. J. Antimicrob. Agents (1993) 3:515–519.
   Google Scholar
• STOCKLEY RA: Role of inflammation in respiratorytract infections. Am. J. Med. (1995) 99:8S–13S.
   Google Scholar
• WOODHEAD MA, MACFARLANE JT, MCCRACKEN JS,ROSE DH, FINCH RG: Prospective study of the aetiology and outcome of pneumonia in the community. Lancet (1987)1 (8534):671–674.
   PubMed Web of Science ®Google Scholar
• MARSTON BJ, PLOUFFE JF, BREIMAN RF et al.: Prelimi-nary findings of a community-based pneumonia inci-dence study. In: Legionella, Proceedings of the Fourth International Symposium. Breiman RF, Barbaree JM, Dufour AP (Eds.) American Society for Microbiology, Washington, DC, USA (1993):36–37.
   Google Scholar
• RESEARCH COMMITTEE OF THE BRITISH THORACIC SO-CIETY AND PUBLIC HEALTH LABORATORY SERVICE: Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortal-ity, prognostic factors and outcome. Quart. J. Med. (1987) 62:195–220.
   PubMedGoogle Scholar
• Pneumonia and influenza death rates - United States,1979-1994. Morbidity and Mortality Weekly Report (1995) 44:535–537.
   PubMedGoogle Scholar
• BACKHOUSE RJ, KAPASI M, NOBLE I, HUTTON J: Model-ling the use of three antibiotics in the management of community acquired pneumonia. Br. J. Med. Econ. (1995) 8:195–210.
   Google Scholar
• BACKHOUSE R, SHAKESPEAR A, HUTTON J: Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bron-chitis. Br. J. Med. Econ. (1995) 8:11–25.
   Google Scholar
• GUEST JF, MORRIS A: Community-acquired lower respi-ratory tract infections: the annual cost to the National Health Service. Br. J. Med. Econ. (1996) 10:263–273.
   Google Scholar
• BARTLETT JG, MUNDY LM: Community-acquired pneu-monia. New Engl. J. Med. (1995) 333:243–250.
   Google Scholar
• VOLMER T: Cost-effectiveness of grepafloxacin as a first-line antibiotic treatment of patients with more se-vere community-acquired lower respiratory infec-tions in Germany. 2nd EGG and 7th BICON. Hamburg, Germany (1998). Abstract T147:72.
   Google Scholar
• FARR BM, MANDELL GL: Gram-positive pneumonia. In: Respirator)/ Infections: Diagnosis and Management. Pen-nington JE (Ed.), Raven Press, New York, USA :298–313.
   Google Scholar
• DAVIES RJ: Respiratory disease. In: Clinical Medicine. Kumar P, Clark M (Eds.), Bailliere Tindall, London, UK (1994):631–708.
   Google Scholar
• DABERNAT H, LEOPHONTE P, BIGNON J et al.: Regional distribution of bacterial strains in acute exacerbation of bronchitis. Med. Mal. Infect. (1994) 24:21–28.
   Web of Science ®Google Scholar
• DOERN GV: Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am. J. Med. (1995) 99:3S–7S.
   Google Scholar
• APPELBAUM PC: Antimicrobial resistance in Strepto-coccus pneumoniae: an overview. Clin. Infect. Dis. (1992) 15:77–83.
   PubMed Web of Science ®Google Scholar
• BAQUERO F: Increasing role of resistance in LRTIs. In-fect. Med. (1998) 15(D):16–27.
   Google Scholar
• LINARES J, PALLARES R, ALONSO T et al.: Trends in anti-microbial resistance of clinical isolates of Streptococ-cus pneumoniae in Bellvitge Hospital, Barcelona, Spain 1979-1990. Clin. Infect. Dis. (1992) 15:99–105.
   PubMed Web of Science ®Google Scholar
• GEORGE RC, BALL LC, COOPER PG: Antibiotic resistant pneumococci in the United Kingdom. Communicable Diseases Report Review (1992) 2:37–42.
   Google Scholar
• OBARO SK, MONTEIL MA, HENDERSON DC: The pneu-mococcal problem. Br. Med. J. (1996) 312:1521–1525.
   PubMed Web of Science ®Google Scholar
• WISE R, ANDREWS JM: Activity of grepafloxacin against respiratory pathogens in the UK. J. Antimicrob. Chemo-ther. (1997) 40 (Suppl. A):27–30.
   Google Scholar
• DOERN GV, BRUEGGEMANN A, HOLLEY HP Jr., RAUCH AM: Antimicrobial resistance of Streptococcus pneu-moniae recovered from outpatients in the United States during the winter months of 1994 to 1995: re-sults of a 30-center national surveillance study. Antimi-crob. Agents Chemother. (1996) 40:1208–1213.
   Google Scholar
• DOMAGALA JM: Structure-activity and structure-side-effect relationships for the quinolone antibacterials. Antimicrob. Chemother. (1994) 33:685–706.
   Web of Science ®Google Scholar
• OWEN K: Grepafloxacin phototoxicity in mouse skin.J. Antimicrob. Chemother. (1998) 42:261–264.
   PubMed Web of Science ®Google Scholar
• FERGUSON J AND DAWE R: Phototoxicity in qui-nolones: comparison of ciprofloxacin and grepafloxa-cin. J. Antimicrob. Chemother. (1997) 40\(Suppl. 493–98.
   Google Scholar
• HALLIWELL RF, DAVEY PG, LAMBERT JJ: Antagonism ofGABA receptors by 4-quinolones. J. Antimicrob. Chemo-ther. (1993) 31:457–62.
   PubMed Web of Science ®Google Scholar
• GREEN MA, HALLIWELL RF: Selective antagonism of theGABAA receptor by ciprofloxacin and biphenylacetic acid. Br. J. Pharmacol (1997) 122:584–590.
   PubMed Web of Science ®Google Scholar
• DAVEY PG: Overview of drug interactions with the qui-nolones. J. Antimicrob. Chemother. (1988) 22 (Suppl. C):97–107.
   Google Scholar
• ITO T, MIURA Y, KADOKAWA T et al.: Effects of enoxacinand its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices. Pharmacol Toxicol. (1991) 68:220–225.
   PubMedGoogle Scholar
• HORI S, SHIMADA J: Effect of grepafloxacin, a newfluoroquinolone on gamma-aminobutyric acid bind-ing: a comparative study of epileptogenic activity of quinolones. Jap. J. Chemother. (1995) 43 (5) :150–154.
   Google Scholar
• SHINTANI S, KUSUNOKI A, HOSOKI E, YAMASHITA S: Drug interaction of OPC-17116, a new quinolone anti-bacterial agent, with nonsteroidal anti-inflammatory drugs in experimental animals. 31st International Con-gress of Antimicrobial Agents and Chemotherapy. Chicago, USA (1991). Abstract 1479.
   Google Scholar
• WAKABE H, MITSUHASHI S: Comparative in vitro activi-ties of a new quinolone OPC-17116, possessing potent activity against Gram-positive bacteria. Antimicrob. Agents. Chemother. (1992) 36:2185–2191.
   PubMed Web of Science ®Google Scholar
• GELLERT M, MIZUUCHI K, O'DEA MH, ITOH T, TOMI-ZAWA J-I: Nalidbdc acid resistance; a second genetic character involved in DNA gyrase activity. Proc. Natl Acad. Sci. USA (1977) 74:4772–4776.
   PubMed Web of Science ®Google Scholar
• SUGINO A, PEEBLES CL, KREUZER KN, COZZARELLI NR:Mechanism of action of nalidixic acid: purification of Escherichia coil nalA gene product and its relation-ship to DNA gyrase and a novel nicking-closing en-zyme. Proc. Natl. Acad. Sci. USA (1977) 75:4767–4771.
   Google Scholar
• KATO J-I, NISHIMURA Y, YAMADA M, SUZUKI H, HIROTAY: Gene organization in the region containing a new gene involved in chromosome partition in Escheri-chia coif j Bacteriol. (1988) 170:3967–3977.
   Google Scholar
• ZECHIEDRICH EL, COZZARELLI NR: Roles of topoi-somerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coif Genes Dev. (1995) 9:2859–2869.
   Google Scholar
• PENG H, MARIANS KJ: Escherichia co/i topoisomeraseIV. Purification, characterization, subunit structure, and subunit interactions. J. Biol. Chem. (1993) 268:24481–24490.
   Google Scholar
• DATA ON FILE: Inhibitory effect of OPC-17116 on topoi-somerase. Microbiological Research Institute, Otsuka Phar-maceutical, (30 June 1995) Report no. 008654.
   Google Scholar
• PAN X-S, FISHER LM: Targeting of DNA gyrase in Strep- tococcus pneumoniae by sparfloxacin: selective tar-geting of gyrase or topoisomerase IV by quinolones.Antimicrob. Agents Chemother. (1996) 40:2321–2326.
   PubMedGoogle Scholar
• ••Until this paper was published it was assumed that allfluoroquinolones primarily targeted topoisomerase IV in S. pneumoniae. However, this work demonstrated that, for some quinolones topoisomerase II may be the most suscep-tible target in S. pneumoniae. This may have important im-plications with respect to development of resistance and activity of newer quinolones against strains of S. pneumo-niaethat are resistant to earlier agents such as ciprofloxacin.
   Google Scholar
• THOMSON KS, SANDERS CC: Dissociated resistance among fluoroquinolones. Antimicrob. Agents Chemo-ther. (1994) 38(9):2095–2100.
   PubMed Web of Science ®Google Scholar
• JOHNSON A: Activity of grepafloxacin against ciprofloxacin-resistant isolates of Streptococcus pneumoniae. 6th International Symposium on New Qui-nolones. Denver, Colorado, USA (1998):Abstract S12.11.
   Google Scholar
• NG EY, TRUCKSIS M, HOOPER DC: Quinolone resistance mutations in topoisomerase IV: relationship of the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. (1996) 40:1881–1888.
   PubMed Web of Science ®Google Scholar
• NG EY, TRUCKSIS M, HOOPER DC: Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistant locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. (1994) 38:1345–1355.
   PubMed Web of Science ®Google Scholar
• TRUCKSIS M, WOLFSON JS, HOOPER DC: A novel locus conferring fluoroquinolone resistance in Staphylo-coccus aureus. J. Bacteriol. (1991) 173:5854–5860.
   PubMed Web of Science ®Google Scholar
• HOOPER DC: Structure of grepafloxacin relative to ac-tivity and safety profile. Gin. Microbiol. Infect. Dis. (1998) 4(1):S15–S20.
   Google Scholar
• GILL MJ, WISER: Activity of grepafloxacin against pneu-mococci resistant to fluoroquinolones by a putative ef-flux mechanism. 38th International Congress of Antimicrobial Agents and Chemotherapy. San Diego, USA (1998). Abstract C52.
   Google Scholar
• SADER H S, ERWIN ME, JONES RN: In vitro Activity Of OPC-17116 Compared To Other Broad-Spectrum Fluoroquinolones. Eur. J. Clin. Microbiol. Infect. Dis. (1992)11 :372–381.
   PubMed Web of Science ®Google Scholar
• MARCO F, JONES RN, HOBAN, DJ, PIGNATARI AC, YA-MANE N, FREI R: In vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multi-centre international study. J. Antimicrob. Chemother. (1994)33:647–754.
   PubMed Web of Science ®Google Scholar
• ROBLIN PM, MONTALBAN G, HAMMERSCHLAG MR: In vi-tro activities of OPC-17116, a new quinolone; ofloxa-cin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob. Agents Chemother. (1994) 38(6)1402–1403.
   Google Scholar
• DUBOIS J, ST-PIERRE C: In vitro susceptibility study of grepafloxacin and other antibiotics against Legionella species. 20th International Congress of Chemotherapy (1997). Abstract 4267.
   Google Scholar
• FUCHS PC, BARRY AL, BROWN SD: Tentative interpre-tive criteria for testing the susceptibility of Streptococ-cus pneumoniae to eight fluoroquinolones. Diagn. Microbiol. Infect. Dis. (1996) 26:23–27.
   PubMed Web of Science ®Google Scholar
• MANDELL LA: Introduction: evolving needs in respira-tory tract infections. Clin. Microbiol. Infect. (1998) 4 (1):S1–S8.
   PubMedGoogle Scholar
• SPANGLER SK, JACOBS MR, APPELBAUM PC: Activity ofCP 99,219 compared with those of ciprofloxacin, met-ronidazole, cefoxitin, piperacillin and piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. (1994) 38:2471–2476.
   PubMed Web of Science ®Google Scholar
• WEXLER HM, MOLITORIS E, FINEGOLD SM: In vitro activ-ity of grepafloxacin (OPC-17116) against anaerobic bacteria. Diagn. Microbic]. Infect. Dis. (1994) 19:129–133.
   PubMed Web of Science ®Google Scholar
• THORNSBERRY C, OGILVIE P, HOLLEY Jr HP, SAHM D: Invitro activity of grepafloxacin and 25 other antimicro-bial agents against Streptococcus pneumoniae: corre-lation with penicillin resistance. Clin. Therapeut. (1998) 20:1179–1190.
   PubMed Web of Science ®Google Scholar
• SADER HS, JONES RN, ALLEN SD et al. In vitro compari-ason activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers. j Chemother. (1993) 5(5) 283–288
   PubMed Web of Science ®Google Scholar
• DASCHNER F, FRANK U, HUBER K: Bactericidal activityof grepafloxacin in comparison to macrolides and other oral antibiotics. 2nd ECC and 7th BICON. Hamburg, Germany (1998):Abstract T148.
   Google Scholar
• PEREZ-VAZQUEZ M, MESEGUER M, MALPICA D, BOU G,CERVE-RO J, MARTINEZ-BELTRAN J: Grepafloxacin (II): Bactericidal activity on Streptococcus pneumoniae and Haemophilus influenzae. 38th International Con-gress of Antimicrobial Agents and Chemotherapy San Di-ego, USA (1998):Abstract E–29.
   Google Scholar
• WIEDEMANN B AND HEISIG P: Antibacterial activity ofgrepafloxacin.j Antimicrob. Chemother. (1997) 40 (Suppl. 419–26.
   Google Scholar
• WIEDEMANN B: The pharmacology of grepafloxacinand ciprofloxacin in an in vitro model with S. pneumo-niae, H. influenzae and M catarrhalis. International Congress of Infectious Diseases (1998):Abstract 13.035.
   Google Scholar
• ZENILMAN JM, NEUMAN T, PATTON M, REICHART C: An-tibacterial activities of OPC-17116, ofloxacin and ciprofloxacin against 200 isolates of Neisseria gonor-rhoeae. Antimicrob. Agents Chemother. (1993) 37(102244–2246.
   Google Scholar
• KENNY GE, CARTWRIGHT FD: Susceptibilities of Myco-plasma hominis, Mycoplasma pneumoniae and Urea-plasma urealyticum to a new quinolone, OPC 17116. Antimicrob. Agents Chemother. (1993) 37(8):1726–1727.
   PubMed Web of Science ®Google Scholar
• RIDGWAY GL, SALMAN H, ROBBINS MJ, DENCER C, FELMINGHAM D: In vitro activity of grepafloxacin against Chlamydia spp, Mycoplasma spp, Urea-plasma urealyticum and Legion ella spp. J. Antimicrob. Chemother. (1997) 40(Suppl. A):31–34.
   Google Scholar
• SANFORD MD, JONES RN: Postantibiotic effects of E-4868 and OPC-17116. J. Antimicrob. Chemother. (1993) 32 (6) :916–917.
   PubMed Web of Science ®Google Scholar
• EFTHYMIOPOULOS C, BRAMER SI, MAROLI A: Pharma-cokinetics of grepafloxacin after oral administration of single and repeat doses in healthy subjects. Clin. Pharmacokinet. (1997) 33(0:1–8.
   PubMedGoogle Scholar
• WISE R: Grepafloxacin pharmacokinetics and tissue penetration in respiratory infections. Clin. Microbiol. Infect. (1998) 4(1):S21–S24.
   PubMedGoogle Scholar
• EFTHYMIOPOULOS C, BRAMER SI, MAROLI A: Effect of food and gastric pH on the bioavailability of gre-pafloxacin. Gun. Pharmacokinet. (1997) 33 (1) :18–24.
   PubMedGoogle Scholar
• EFTHYMIOPOULOS C, BRAMER SL, MAROLI A: Effect of age and gender on the pharmacokinetics of gre-pafloxacin. Clin. Pharmacokinet. (1997) 33 (1)9–17.
   Google Scholar
• COOK PJ, ANDREWS JM, WISE R et al.: Pharmacokinetics of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J. Antimicrob. Chemo-ther. (1995) 35:317–326.
   PubMed Web of Science ®Google Scholar
• CHILD J, ANDREWS JM, WISE R: Pharmacokinetics and tissue penetration of the new fluoroquinolone gre-pafloxacin. Antimicrob. Agents Chemother. (1995) 39(2):513 515.
   PubMed Web of Science ®Google Scholar
• HONEYBOURNE D, ANDREWS JM, JEVONS G et al: Pene-tration of levofloxacin into lung tissue after a single 500 mg oral dose. 8th European Congress of Clinical Mi-crobiology and Infectious Diseases. Lausanne, Switzerland (1997). Abstract P377.
   Google Scholar
• WISE R, HONEYBOURNE D: A review of the penetration of sparfloxacin into the lower respiratory tract and si-nuses. J. Antimicrob. Chemother. (1996) 37\(Suppl. 457–63.
   Google Scholar
• ANDREWS J, BRENWALD N, WISE R, HONEYBOURNE D: Concentrations of trovafloxacin in lung tissue. 36th In-terscience Conference on Antimicrobial Agents and Chemo-therapy New Orleans, USA (1996). Abstract A4.
   Google Scholar
• EFTHYMIOPOULOS C, BRAMER SL, MAROLI A, GAMBER-TOGLIO JG: Effect of renal impairment of pharmacoki-netics of grepafloxacin. Gun. Pharmacokinet. (1997) 33(1):32–38.
   PubMedGoogle Scholar
• EFTHYMIOPOULOS C, BRAMER SL, MAROLI A et al.: Gre-pafloxacin pharmacokinetics in subjects with hepatic dysfunction. Clin. Pharmacokinet. (1997) 33 (1) 25–31.
   PubMedGoogle Scholar
• EFTHYMIOPOULOS C: Pharmacokinetics of grepafloxa-cin. J. Antimicrob. Chemother. (1997) 40\(Suppl. 435–44.
   Google Scholar
• EFTHYMIOPOULOS C, BRAMER SL, MAROLI A, BLUM B: Theophylline and warfarin interaction studies with grepafloxacin. Clin. Pharmacokinet. (1997) 33(1)39–46.
   Google Scholar
• O'DOHERTY B, DUTCHMAN DA, PETTIT R, MAROLI A: Randomised, double-blind, comparative study of gre-pafloxacin and amoxycillin in the treatment of pa-tients with community-acquired pneumonia. J. Antimicrob. Chemother. (1997) 40\(Suppl. 473–81.
   Google Scholar
• ADAMS M, SULLIVAN J, HENRY D et al.: Comparison of grepafloxacin with cefaclor in the treatment of community-acquired pneumonia. 37th International Congress of Antimicrobial Agents and Chemotherapy. To-ronto, Canada (1997). Abstract LM68.
   Google Scholar
• PATEL T, DESAI R, DUFF J, JOHNSON ME, BREISCH SA, MAROLI AN: Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia. 37th International Congress of An-timicrobial Agents and Chemotherapy. Toronto, Canada (1997). Abstract LM69.
   Google Scholar
• TOPKIS S, SWARZ H, BREISCH SA, MAROLI AN: Efficacy and safety of grepafloxacin, 600 mg q.d. for 10 days, in patients with community-acquired pneumonia. Curr. Ther. Res. (1997) 19(5):975–988.
   Google Scholar
• LANGAN CE, CRANFIELD R, BREISCH S, PETTIT R: Ran-domised, double-blind study of grepafloxacin vs amoxycillin in patients with acute bacterial exacerba-tions of chronic bronchitis. J. Antimicrob. Chemother. (1997) 40(Suppl. A):63–72.
   Google Scholar
• CHODOSH S, LAKSHMINARAYAN S, SWARZ, H et al.: The efficacy and safety of a 10-day course of grepafloxacin 400 mg once daily in the treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of ciprofloxacin 500 mg twice daily. Antimicrob. Agents Chemother. (1998) 42 (1) :114–120.
   PubMed Web of Science ®Google Scholar
• DEABATE CA, BETTIS R, MUNK ZM et al.: Effectiveness of short-course therapy (5 Days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. an. Ther (1999) 21:172–188.
   Google Scholar
• OWEN K: Joint toxicity following intravenous admini-stration of grepafloxacin, ciprofloxacin and ofloxacin to dogs. 37th International Congress of Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997). Ab-stract A101.
   Google Scholar
• CHODOSH S: Clinical efficacy and tolerability of gre-pafloxacin in lower respiratory tract infection. Clin. Microbiol. Infect. (1998) 4(1):S25–S31.
   PubMedGoogle Scholar
• LODE H, VOGEL F, ELIES W: Grepafloxacin: a review of its safety profile in clinical trials and post-marketing surveillance. Clin. Ther. (1999) 21(1):61–74.
   PubMed Web of Science ®Google Scholar
• TSCHIDA SJ, GUAY DR, HOEY LL et al: QTc prolongation associated with slow intravenous erythromycin lacto-bionate infusions in critically ill patients: a prospec-tive evaluation and review of the literature. Pharmacotherapy (1996) 16(4):663–674.
   PubMed Web of Science ®Google Scholar
• MCFARLANE JT, COLVILLE A, GUION A et al.: Prospective study of aetiology and outcome of lower respiratory tract infections in the community. Lancet (1993) 341:511–514.
   PubMed Web of Science ®Google Scholar